DIA.PRO Diagnostic BioProbes Srl of Sesto San Giovanni (MI) at MEDICA 2020 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

DIA.PRO Diagnostic BioProbes Srl

Via G. Carducci, 27, 20099 Sesto San Giovanni (MI)
Italy
Telephone +39 02 27007161
Fax +39 02 44386771
info@diapro.it

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Contact

Edoardo Marchisio

Director
Sales & Marketing

Phone
+39 347 0718232

Email
edoardomarchisio@diapro.it

Marino Marchisio

Technical Director
Research & Development

Phone
+39 338 6476972

Email
mmarchisio@diapro.it

Diego Di Palma

Business Development

Phone
+39 340 2584229

Email
diego.dipalma@diapro.it

Cristina Scozzesi

Manager
Strategic Reagents

Phone
+39 347 1597375

Email
cristina.scozzesi@diapro.it

Giovanni Mascolo

Manager
QC & Production

Phone
+39 342 3602362

Email
giovanni.mascolo@diapro.it

Zay Asvat

Marketing & Sales Executive

Phone
+39 02 35969406

Email
zay.asvat@diapro.it

Kolthum El Joulani

Sales & Marketing - Middle East and North Africa

Phone
+39 3426123549

Email
kolthum.eljoulani@diapro.it

Piero Alivernini

Instruments Unit Manager
Automation

Phone
+39 344 0418086

Email
piero.alivernini@diapro.it

Sandro Acquaviva

Instrument & Product Specialist
Automation / CLIA

Phone
+39 3402313376

Email
sandro.acquaviva@diapro.it

Stefania Simonelli

Purchasing

Phone
+390235969431

Email
stefania.simonelli@diapro.it

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.05  Infectious immunology testing
  • 03.05.03  Other infectious immunology testing

Our products

Product category: Other infectious immunology testing

S.A.R.A./CLIA Random Access analyser & Kits

Fully automated bench top analyzer with continuous random access. Chemi Luminescence Random Access analyser based on magnetic particles. Closed CLIA System

S.A.R.A.: Main Features
Productivity and speed: 120 samples/hour; first result after 30/45 min; second reading after 30 seconds
Samples identification: BarCode reader
Sample addition: Disposable tips. Volume per sample 10-200 μl
Solid phase: Magnetic Beads
Incubation temperature: 37 °C
Reading system: Chemiluminescence
Operator interface: LCD touch screen

More Less

Product category: Other infectious immunology testing

ELISA screening assays

  • DIA.PRO is the sole manufacturer of a complete ELISA panel able to meet every blood bank screening requirement worldwide.
    Highly sensitive and specific assays to assure superior performance and reliable results
    CE marked - Entirely manufactured in Italy
    Assay protocols can be easily carried out by automatic ELISA work station
    Assays are adapted to the DIA.PRO fully automated work station DIA.BLO OD
    Common Components for all the Kits
    Monitorable samples and reagents addition by color change

    ELISA Portfolio: 
COVID-19: IgM+IgG+IgA+IgG Conf+Spike 1&2 IgG
Viral Hepatitis: A+B+C+D+E
Retroviruses: HIV Combo; HTLV I&II Ab
Flavivirus Pathogens: Dengue, Zika, Chickungunya, Yellow Fever, West Nile
TO.R.C.H.: IgG & capture IgM
Epstein Barr: EBNA+VCA+Ea
Helicobacter pylori: Ag & Ab
Chlamydia Trachomatis & Pneumoniae: IgG+IgA+IgM
Tropical Serology: Malaria, Chagas
Autoimmunity: ANA, ENA
Vaxination Follow Up: Tetanus, Meningitis, Measles

More Less

Product category: Other infectious immunology testing

RealTime PCR

Dia.Pro offers a complete line of RealTime PCR top quality molecular diagnostic kits for infectious diseases.

Main features:
CE certified
 Kits contain all reagents necessary to carry out test
 Internal control to verify DNA extraction & amplification
 Quantitive tests: standard curve on 4 points
High Sensitivity & Specificity
 Samll Reaction volume of 25μl: 20 μl reaction Mix + 5 μl samples
 Sample: Blood, Serum & Plasma, Liquor, Biopsies
 Storage temperature: +2/8°C (no shipment in dry ice needed)
 Shelf life: 12 months at +2/8°C
 Kit format: 25,50,100,150 reactions: no waste

 

More Less

Product category: Other infectious immunology testing

DIA.BLOod / ELISA blood screening

The use of ELISA automated workstations is recommended for blood screening.
DIA.PRO designed DIA.Blood DUO, a fully automated ELISA workstation specifically for blood screening and large volume testing

In the screening for blood-born infectious diseases (Hepatitis, RetroViruses, Tropical Diseases, etc.) and the determination of markers of widely spread pathologies (TORCH, Autoimmunity, etc.)

A fully automated system of analysis plays an important role in the laboratory, providing the best integration between a workstation able to carry out the complete analytical process and dedicated high performance "in vitro" diagnostic kits.

More Less

Product category: Other infectious immunology testing

COVID-19 DIAGNOSIS - RT-PCR / ELISA / CLIA

  • ELISA kits:

    COVID-19 IgM
    Monitoring of the immune response to COVID-19, in the early stage of the infection as an additional marker to PCR
    COVID-19 IgA
    The IgA assay is recommended, in addition to IgG and IgM, to:
    (a) monitor the global immunological response of patients undergoing an acute infection and their follow-up to full recovery;
    (b) specifically for testing patients with symptoms of the gastroenteric form of COVID-19 infection;
    COVID-19 IgG
    Monitoring of the immune response to COVID-19. Recommended in particular for testing:
    (a) infected individuals in follow-up serological testing and when recovered from the infection, negative for COVID-19 PCR, to assure they developed IgG antibodies to the virus, confirming a full recovery from the infection;
    (b) health-care workers at risk of covid-19 infection to verify whether or not they developed IgG antibodies to the virus;
    (c) individuals from normal population to study their acquired immune status against COVID-19 infection.
    (d) human antibodies donors for a preliminary screening of hyper-immune sera as a possible candidate for an immunotherapeutic approach to the treatment of the disease;
    COVID-19 IgG Confirmation
    Module-based Enzyme-Immuno-Assay for the Confirmation/typing of human samples screened as positive for IgG. The test is aimed to identify the specificity of antibodies to the major immunodominant COVID-19 antigens Nucleocapsid, Spike1 and Spike2
    COVID-19 Spike 1&2 IgG
    Semi-quantitative determination of IgG antibodies to COVID-19 Spikeantigens. Intended for testing:
    a) health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing antiSpike IgG;
    b) normal population for epidemiology studies on presence of potential “protective” IgG to COVID-19 Spike antigens;
    c) PCR-negative infected individuals, successfully recovered from infection, to assure presence of potentially neutralizing antibodies;
    d) human donors, recovered from COVID-19 infection, positive for anti-Spike IgG for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease;
    e) vaccinated individuals to assure a reliable positive immunization with development of anti Spike IgG antibodies;
    COVID-19 IgG/IgM Confirmation and Typing
    Module-based Enzyme-Immuno-Assay for the Confirmation of samples positive for IgG and IgM antibodies to COVID 19 in first screening
 

  • RT-PCR kit:
COVID-19 RNA
Lyophilized Real-Time RT-PCR assay for the detection of novel Coronavirus SARS-CoV-2. One Step Multiplex Real-Time PCR mix. Highly specific;  


  • CLIA kits:

    SARS-CoV-2  IgM
    Monitoring of infected patients.In addition the kit may be used when testing the population and and health-care workers looking for potentially infective “pauci” or  a-symptomatic individuals in the early phase of infection, in combination with  SARS-COV-2 molecular tests.
    SARS-CoV-2  IgA
    Monitoring of infected patients.In addition the kit may be used when testing the population and and health-care workers looking for potentially infective “pauci” or a-symptomatic individuals in the early phase of infection, in combination with SARS-COV-2 molecular tests.
    SARS-CoV-2 IgG
    Monitoring of infected patients.In addition the kit may be used when testing the population and and health-care workers looking for potentially infective “pauci” or a-symptomatic individuals in the early phase of infection, in combination with SARS-COV-2 molecular tests.
    SARS-CoV-2 Spike/RBD Ab
    Intended for testing:
    (a) health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing anti Spike antibodies.
    (b) normal population for epidemiology studies on presence of potential “protective” Antibodies to SARS-CoV-2 Spike antigens;
    (c) PCR-negative infected individuals, successfully recovered from infection, to assure presence of potentially neutralizing antibodies;
    (d) human donors, recovered from COVID--19 infection, positive for anti--Spike I Antibodies for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease;
    (e) vaccinated individuals to assure a reliable positive immunization with development of anti Spike Antibodies;

     

More Less

Company news

Date

Topic

Download

Nov 3, 2020

CORONAVIRUS COVID-19 / SARS-CoV-2 Assays

COVID 19 DISEASE
The 2020 global diagnostic challenge

Dia.Pro offers Assay solutions, to assist scientific experts in addressing the COVID-19 Pandemic.
100% MADE IN ITALY
CE MARKED
ADAPTABLE ON THE MOST COMMON PROCESSING SYSTEMS

ELISA kits:

COVID 19 IgM
:
Monitoring of the immune response to COVID 19 in the early stage of the infection as an additional marker to PCR

COVID 19 IgA :
The IgA assay is recommended, in addition to IgG and IgM, to
(a) monitor the global immunological response of patients undergoing an acute infection and their follow up to full recovery
(b) specifically for testing patients with symptoms of the gastro enteric form of COVID 19 infection

COVID 19 IgG:  Monitoring of the immune response to COVID 19 Recommended in particular for testing
(a) infected individuals in follow up serological testing and when recovered from the infection, negative for COVID 19
PCR, to assure they developed IgG antibodies to the virus, confirming a full recovery from the infection
(b) health care workers at risk of covid 19 infection to verify whether or not they developed IgG antibodies to the virus
(c) individuals from normal population to study their acquired immune status against COVID 19 infection
(d) human antibodies donors for a preliminary screening of hyper immune sera as a possible candidate for an
immunotherapeutic approach to the treatment of the disease

COVID 19 IgG Confirmation: 
Module based Enzyme Immuno Assay for the Confirmatiogn typing of human samples screene d as positive for IgG The test is aimed to identify the specificity of antibodies to the major immunodominant COVID 19 antigens Nucleocapsid, Spike 1 and Spike 2

COVID 19 Spike 1 2 IgG: S
emi quantitative determination of IgG antibodies to COVID 19 Spike antigens Intended for testing
a) health care workers at risk of COVID 19 infection to verify whether or not they might be positive for potentially
neutralizing anti Spike IgG
b) normal population for epidemiology studies on presence of potential “ IgG to COVID 19 Spike antigens
c) PCR negative infected individuals successfully recovered from infection, to assure presence of potentially
neutralizing antibodies
d) human donors recovered from COVID 19 infection, positive for anti Spike IgG for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease e) vaccinated individuals to assure a reliable positive immunization with development of anti Spike IgG antibodies;

COVID 19 IgG/IgM Confirmation and Typing :
Module based Enzyme Immuno Assay for the Confirmation of samples positive for IgG and IgM antibodies to COVID 19 in first screening.


Real Time PCR kit

COVID 19 RNA: 
Specific qualitative detection of SARS CoV 2 in human samples by amplification of RdRp and N gene A simultaneous control of the extraction/amplification reaction through the RNA sequence of an endogenous Internal Control (IC)

More Less

About us

Company details

A privately owned company, founded in 1996 in Milan Italy, with over 30 years of International experience & expertise in the field of Immuno Diagnostics for infectious diseases.

Our team consists of a staff of professional dedicated experts, originating from Global IVD leading companies.
Extensive experience in automation & assay development, matured on market leader instruments.
In-house development and production of monoclonal antibodies, recombinant proteins, synthetic peptides & native highly purified antigens. Certification for UNE-EN ISO 13485:2018 & CE in accordance with Annex IV, Section 4, Directive 98/79/EC.

We offer an OEM production of CE marked DiaPro products/Immunoassays, through individual contracts of supply, providing the customer access DiaPro’s CE Design Dossiers & certification, to speed up the process of acquiring their own CE mark.
Development Projects for Diagnostic systems, by providing skilled & professional partnership &/or R&D contracts in assay development, performance evaluation trials and CE-marking of the assays.
Partnership in development Projects of new straight forward diagnostic devices, based on innovative technologies & new strategic reagents.
Technology Transfer dedicated to companies interested in extending their product range, on new devices or manufacturing in emerging countries.

OUR MISSION

Profitable growth & building long-term fruitful relationships, through superior Customer Service, Innovation, Excellent Quality and Commitment.

More Less

Company data

Sales volume

10-49 Mio US $

Export content

> 75%

Number of employees

50-99

Foundation

1996

Area of business

Diagnostics

Company information as a PDF file